Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200910 | 0.86 | CCNB2 (0.52) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL8161649 | 0.81 | SIRT2 (0.49) | HDAC1NR1H4TRPV1ESR1EPHX2 | |
| SCHEMBL8161645 | 0.81 | SIRT2 (0.49) | HDAC1NR1H4TRPV1ESR1EPHX2 | |
| SCHEMBL1093134 | 0.80 | AHR (0.49) | HDAC1AHRSMYD3GRIA1CACNG8 | |
| SCHEMBL1093132 | 0.80 | AHR (0.49) | HDAC1AHRSMYD3GRIA1CACNG8 | |
| Hydrochloric Acid SCHEMBL1092481 | 0.79 | AHR (0.47) | HDAC1AHRSMYD3GRIA1CACNG8 | |
| Hydrochloric Acid SCHEMBL1092478 | 0.79 | AHR (0.47) | HDAC1AHRSMYD3GRIA1CACNG8 | |
| SCHEMBL27121673 | 0.75 | PTPN1 (0.52) | CRBNCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL26007742 | 0.75 | HDAC1 (0.48) | HDAC1NR1H4TRPV1ESR1 | |
| SCHEMBL27484774 | 0.74 | CRBN (0.51) | CRBNCCNB2CDK1CCNB1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | CRBN 3584/4885CCNB2 700/4885CDK1 414/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | CRBN 3456/4885CCNB2 3182/4885CDK1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.